Victrex plc VCT
LSE · United Kingdom · Process Industries
GBp 927.00+4.00 (+0.43%)
Market open· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Victrex (VTXPF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The specialist polymer maker jumped around 15% after stronger aerospace, electronics and Asian demand pushed full-year profit guidance higher.
[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Implantable Cardiac Fluorine-Free Resins Market size & share revenue was valued at approximately USD 1.52 Billion in 2025 and is expected to reach USD 1.67 Billion in 2026 and is expected to reach around USD 4.26 Billion by 2035, at a CAGR of 10.8% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Covestro
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.